SCHEMBL7425669

SCHEMBL7425669

CCCCC(NC(=O)c1ccc(NS(=O)(=O)c2ccc3ccccc3c2)cc1)C(=O)CNS(C)(=O)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HDAC1 Q13547 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
PLAU P00749 3/20 0.48
ATM Q13315 1/20 0.47
KAT6A Q92794 2/20 0.45
CA2 P00918 2/20 0.45
GPR27 Q9NS67 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7682470 0.92 ALDH1A1 (0.51) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7427436 0.91 AKR1C3 (0.45) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7665000 0.89 ALDH1A1 (0.52) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7654043 0.89 ALDH1A1 (0.54) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7428036 0.89 CA2 (0.45) LMNASMN1; SMN2HDAC1HDAC3HDAC2
SCHEMBL7706585 0.86 ALDH1A1 (0.53) ALDH1A1LMNAGAASMN1; SMN2HDAC1
SCHEMBL7680584 0.83 AKR1C3 (0.48) ALDH1A1LMNAGAASMN1; SMN2PLAU
SCHEMBL7684139 0.83 CA2 (0.48) ALDH1A1LMNAGAASMN1; SMN2KAT6A
SCHEMBL7659849 0.82 AKR1C3 (0.47) ALDH1A1LMNAGAASMN1; SMN2PLAU
SCHEMBL7683061 0.81 PYGL (0.43) LMNASMN1; SMN2KAT6ACA2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436925-B1 BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES ABBOTT LABORATORIES 2002-08-20 US disclosed
EP-1073632-A1 SUBSTITUTED BENZAMIDES, THEIR PRODUCTION AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-02-07 EP disclosed
WO-1999054293-A1 SUBSTITUTED BENZAMIDES, THEIR PRODUCTION AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1999-10-28 WO disclosed